LOTTE Biologics Recognized for Excellence in CDMO Services
LOTTE Biologics (Co-CEOs James Park and Shin Yooyeol) has been awarded at the 2026 CDMO Leadership Awards, a prestigious recognition within the global contract development and manufacturing organization (CDMO) industry. The award acknowledges the company’s rapid growth and commitment to quality in the biopharmaceutical sector.
CDMO Leadership Awards: A Benchmark for Excellence
The CDMO Leadership Awards, hosted by Outsourced Pharma and Life Science Connect, evaluate companies based on a comprehensive assessment of their capabilities, quality, reliability, and service. Evaluations are drawn from feedback provided by decision-makers at global pharmaceutical and biotech firms who have collaborated with nominees within the past 24 months.
The awards’ credibility is further strengthened by an independent review conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD). Nominations are accepted only from clients or industry peers, ensuring objectivity and independence from marketing influences.
“Best New or Relaunched CDMO” Award Highlights LOTTE Biologics’ Success
LOTTE Biologics received the “Best New or Relaunched CDMO” category award, recognizing companies that have successfully entered the market or restructured their business, earning trust from global partners through differentiated competitiveness and a clear strategy.
This achievement comes just four years after LOTTE Biologics’ launch, demonstrating its rapid brand recognition and the quality of its CDMO services.
Strategic Initiatives Drive Recognition
Industry observers have noted LOTTE Biologics’ “dual site” strategy as a key factor in its success. The company has secured over 62 global regulatory approvals and is expanding its capabilities in antibody-drug conjugates (ADCs).
LOTTE Biologics is also focused on the development of its Songdo Bio Campus, expanding its portfolio beyond monoclonal antibodies to include ADCs, solidifying its position in the next-generation biopharmaceutical market.
Commitment to Partnership and Value Creation
A company representative stated that the award is meaningful as it reflects recognition earned within a short period in the global CDMO market. LOTTE Biologics aims to strengthen its role as a partner delivering tangible value to the global biopharma ecosystem.
Expanding Strategic Partnerships
During DCAT Week, LOTTE Biologics hosted private meetings at the Lotte New York Palace Hotel to actively engage in business discussions and expand strategic partnerships with global pharmaceutical and biotech companies.